The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTK-Cys481 ibrutinib resistance

Guang Yang, Jinhua Wang, Li Tan, Manit Munshi, Xia Liu, Amanda Kofides, Jiaji G. Chen, Nicholas Tsakmaklis, Maria G. Demos, Maria Luisa Guerrera, Lian Xu, Zachary R. Hunter, Jinwei Che, Christopher J. Patterson, Kirsten Meid, Jorge J. Castillo, Nikhil C. Munshi, Kenneth C. Anderson, Michael Cameron, Sara J. Buhrlage, Nathanael S. Gray, and Steven P. Treon

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTK-Cys481 ibrutinib resistance

blood® 18 NOVEMBER 2021 | VOLUME 138, NUMBER 20